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Aim: Metabolic syndrome (MetS) is a clustering of factors that are associated with increased 
cardiovascular risk. We aimed to investigate the proportion of patients with MetS in patients 
undergoing cardiac rehabilitation (CR), and to describe differences between patients with 
MetS compared to those without MetS with regard to (1) patient characteristics including 
demographics, risk factors, and comorbidities, (2) risk factor management including drug 
  treatment, and (3) control status of risk factors at entry to CR and discharge from CR.
Methods: Post-hoc analysis of data from 27,904 inpatients (Transparency Registry to Objectify 
Guideline-Oriented Risk Factor Management registry) that underwent a CR period of about 
3 weeks were analyzed descriptively in total and compared by their MetS status.
Results: In the total cohort, mean age was 64.3 years, (71.7% male), with no major differences 
between groups. Patients had been referred after a ST elevation of myocardial infarction event in 
41.1% of cases, non-ST elevation of myocardial infarction in 21.8%, or angina pectoris in 16.7%. 
They had received a percutaneous coronary intervention in 55.1% and bypass surgery (coronary 
artery bypass graft) in 39.5%. Patients with MetS (n = 15,819) compared to those without MetS 
(n = 12,085) were less frequently males, and in terms of cardiac interventions, more often received 
coronary artery bypass surgery. Overall, statin use increased from 79.9% at entry to 95.0% at 
discharge (MetS: 79.7% to 95.2%). Patients with MetS compared to those without MetS received 
angiotensin converting enzyme inhibitors, angiotensin receptor blockers, oral antidiabetics, and 
insulin at entry and discharge more frequently, and less frequently clopidogrel and aspirin/clopidogrel 
combinations. Mean blood pressure was within the normal range at discharge, and did not differ 
substantially between groups (124/73 versus 120/72 mmHg). Overall, between entry and discharge, 
levels of total cholesterol, low density lipoprotein cholesterol, and triglycerides were substantially 
lowered, in particular in MetS patients. Thus, control rates of lipid parameters improved substantially, 
with the exception of high density lipoprotein cholesterol. Low density lipoprotein cholesterol rates 
,100 mg/dL increased from 38.7% at entry to 73.8% at discharge (MetS: from 39.4% to 74.6%) 
and triglycerides control rates (,150 mg/dL) from 58.1% to 70.4% (MetS: 43.7% to 62.2%). 
Physical fitness on exercise testing improved substantially in both groups.
Conclusion: Patients with and without MetS benefited substantially from the participation 
in CR, as their lipid profile, blood pressure, and physical fitness improved. Treatment effects 
were similar in the two groups.
Keywords: cardiac rehabilitation, registry, metabolism, diabetes, dyslipidemia, control rates, 
risk factor, lipids
Introduction
Despite a declining incidence in recent years, cardiovascular events remain a leading 
cause of morbidity and mortality in most regions worldwide. In clinical practice, 
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the prediction of such events to identify patients at high 
  cardiovascular risk and to offer them preventive measures is 
of high priority.1 Substantial research has been performed on 
the clustering of cardiovascular risk factors named metabolic 
syndrome (MetS) and the question whether this clustering 
represents a disease entity in its own right. At least five 
  definitions with slight or moderate deviations from each 
other have been proposed by international organizations or 
by expert groups.2–7 The most frequently used ones have been 
issued by the National Cholesterol Education Program Adult 
Treatment Panel (NCEP ATP) III5 and by the International 
Diabetes Federation (IDF).7
A setting with a known high prevalence of patients 
with MetS is cardiac rehabi  li  tation (CR). CR is primarily 
indicated for patients who have received a diagnosis of 
acute myocardial infarction, have undergone coronary 
revascularization, or have chronic stable angina.8,9 The goals 
of CR and secondary prevention involve a program of 
prescribed exercise and interventions designed to modify 
coronary risk factors, including drug therapy. The aims 
are to prevent disability resulting from coronary disease, 
particularly in elderly persons and those with occupations 
that involve physical exertion, and to prevent subsequent 
coronary events, subsequent hospitalization, and death from 
cardiac causes.8 The benefits of CR are broad and compelling. 
Exercise together with nutritional counseling can slow the 
atherosclerotic process10,11 and lead to lower rates of cardiac 
events and hospitalizations.10,12 In a review of 22 studies, an 
average mortality reduction of 20% has been described for 
patients who underwent CR with exercise.13
In Germany, the transfer of cardiac patients from the 
hospital to the CR clinic is an established procedure with low 
barriers, and is particularly independent of socioeconomic 
status. Thus the situation represents not usual but rather best 
practice, which can be analyzed to investigate effectiveness 
of therapy under real practice conditions.9,14
It can be expected that a higher percentage of cardiac 
patients in CR fulfill the definition of MetS, but to date 
no specific data have been reported in this setting. The 
Transparency Registry to Objectify Guideline-Oriented Risk 
Factor Management (TROL) is one of the largest registries 
on CR and has been used, among others, for the description 
of secular trends in the management of patients in “real-
world” CR.15 We performed a post-hoc analysis of data of 
the registry with the aim to investigate the proportion of 
patients with MetS in patients undergoing CR, and to describe 
differences between patients with MetS compared to those 
without MetS using the IDF definition7 with regard to (1) 
patient characteristics including demographics, risk factors, 
and comorbidities, (2) risk factor management including 
drug treatment, and (3) control status of risk factors at entry 
to CR and discharge from CR.
Methods
Source of data
TROL is a large scale prospective registry set up in 2003 
under the auspices of the German Society for Prevention 
and Rehabilitation.16 Centers were eligible to participate 
if they had a significant number of CR patients, and were 
selected across Germany to ensure that all 16 federal states 
were   represented adequately.15,17 Participating physicians 
  documented inpatients on standardized case report forms. 
The ethics committee of the Bavarian Physician Chamber 
approved the study, and all patients provided informed 
consent. Patient data protection was ensured. We report 
an analysis of the dataset of the years 2005 to 2008, which 
comprises 27,904 patients with adequate and complete 
information to decide on the presence of MetS.
CR program
CR programs are not standardized in Germany in terms of 
type (eg, inpatient versus outpatient), length, structure, or 
components. However, the vast majority of patients undergo 
in-hospital rehabilitation therapy usually for 3–4 weeks.9 Key 
features of these programs are gradual increase in activity 
levels, continuation of risk factor modifications (eg, lipid 
lowering), and development of maintenance programs.9,15
Variables
The following patient characteristics were recorded: 
(1) demographics: age, gender, body mass index (BMI); 
(2) length of stay: rehabilitation beginning and end; (3) risk 
factors (diabetes mellitus, hyperlipoproteinemia, arterial 
hypertension, smoking, positive cardiac family history); 
(4) concomitant diseases: peripheral arterial disease, previous 
stroke; (5) systolic and diastolic blood pressure at entry and 
discharge; (6) laboratory parameters at entry and discharge: 
total cholesterol (TC, mg/dL), low density lipoprotein 
cholesterol (LDL-C, mg/dL), high density lipoprotein cho-
lesterol (HDL-C, mg/dL), triglycerides (TG, mg/dL), fast-
ing blood glucose (mg/dL); (7) cardiopulmonary exercise 
testing (Watts); (8) medication use at entry and discharge: 
statins, acetylic salicylic acid (ASA, aspirin), beta blockers, 
angiotensin converting enzyme (ACE) inhibitors, angiotensin 
receptor antagonists (ARB), oral antidiabetic drugs, insulin, 
and other drugs.
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Table 1 IDF definition of MetS7,40
Parameter Explanation
Central obesity Defined as waist circumference $94 cm for 
European men and $80 cm for European 
women, with ethnicity specific values for other 
groups*
plus any two of the 
following four factors:
Raised TG $1.7 mmol/L (150 mg/dL)  
or specific treatment for this lipid abnormality
Reduced HDL-C ,1.03 mmol/L (40 mg/dL) in males  
,1.29 mmol/L (50 mg/dL) in females  
or specific treatment for this lipid abnormality
Raised blood pressure Systolic: $130 mmHg or diastolic: $85 mmHg  
or treatment of previously diagnosed 
hypertension
Raised plasma  
glucose**
Fasting plasma glucose $5.6 mmol/L (100 mg/dL)  
or previously diagnosed type 2 diabetes
Notes: *If BMI is .30 kg/m2, central obesity can be assumed and waist circumference 
does not need to be measured; **In clinical practice, impaired glucose tolerance is 
also acceptable, but all epidemiological reports of the prevalence of MetS should use 
only fasting plasma glucose and presence of previously diagnosed diabetes to assess 
this criterion. Prevalence also incorporating 2-hour glucose results can be added as 
supplementary findings.
Abbreviations: IDF, International Diabetes Federation; MetS, metabolic syndrome; 
TG, triglycerides; HDL-C, high density lipoprotein cholesterol; BMI, body mass index.
Patients were categorized as having MetS if they met the 
definition of the IDF 20057 (Table 1).
Statistical analysis
Data are presented as absolute numbers, percentages, or 
means with standard deviations (SD). The frequencies of 
categorical variables in populations were compared by Chi 
square test. Continuous variables were compared by two-
tailed Wilcoxon rank sum test. Percentages were calculated 
on the basis of patients with data for each respective 
parameter (ie, no percentages for missing values provided). 
The analysis was performed with the SAS (v9.1; SAS 
Institute Inc, Cary, NC).
Results
Patient demographics and characteristics
Total cohort
A total of 27,904 patients with information on MetS (15,819 
with MetS/12,085 without MetS) were available (in 2005: 
5805; 2006: 8839; 2007: 5753; 2008: 7507 patients). The 
majority of patients were fully or partly institu  tionalized 
for CR (95.3% or 1.4%, respectively). Mean duration of 
rehabili  tation was 21.4 ± 37.5 days, with a trend towards an 
increase over the years (2005: 19.8 days; 2006: 20.3 days; 
2007: 22.9 days; 2008: 22.7 days). The majority of patients 
were retired (61.5%).
Demographic and clinical characteristics are summarized 
in Table 2. The proportion of males in total was 71.7%, 
the average age 64.3 ± 11.5 years, the mean BMI was 
28.4 ± 4.8 kg/m2. Cardiovascular risk factors were highly 
prevalent as expected, in particular lipid disorders (97.1%), 
diabetes mellitus (35.7%), arterial hypertension (86.9%), and 
former or current smoking (47.7% and 15.7%, respectively). 
In addition to coronary artery disease, 12.2% of patients 
also had peripheral artery disease, and 8.8% had had a prior 
stroke event.
Patients with ST elevation myocardial infarction (STEMI) 
were the largest group (41.1% of patients), followed by non-
ST elevation myocardial infarction (NSTEMI; 21.8%) and 
instable angina pectoris (16.7%). In terms of therapy at the 
acute hospital, percutaneous coronary intervention was more 
often reported compared to coronary artery bypass graft 
(55.1% versus 39.5%, respectively).
Subgroups with and without MetS
Due to the large sample size, statistically significant 
  differences between the two subgroups were noted for all 
mentioned demographic and clinical characteristics with 
the exception of NSTEMI. Patients with MetS compared to 
those without MetS were less frequently men, and naturally 
differed with respect to components of the MetS definition 
(having a higher BMI, a higher waist circumference, more 
often hypertension, and substantially more often diabetes 
(52% versus 14%, respectively). Mean fasting glucose was 
higher in patients with MetS compared to those without 
MetS (115 mg/dL versus 98 mg/dL), as was glycosylated 
hemoglobin (HbA1c; 6.6% versus 6.1%). In terms of   cardiac 
interventions, patients with MetS more often received 
  coronary artery bypass graft surgery.
Drug utilization
Total cohort
Drug treatment at entry and discharge is shown in Table 3. 
In the total cohort, the majority of patients received statins at 
entry (any drug in 79.9%). In particular, simvastatin (61.0%, at 
a mean dose of 30.4 mg/day), atorvastatin (7.0%, mean dose 
28.9 mg/day), and fluvastatin (7.9%, mean dose 60.2 mg/day) 
were reported. At the end of CR stay, almost all patients 
received statin therapy (any statin in 95.2%). The rates of 
simvastatin use increased, while all other statins decreased 
somewhat. Furthermore, overall the respective mean dosages 
increased slightly, eg, for atorvastatin to 32.3 mg/day.
Treatment with cholesterol absorption inhibitors 
increased substantially during the CR (from 7.2% to 47.2%). 
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ASA use remained nearly unchanged at a high level 
(at   discharge 84.2%), while clopidogrel alone or in combi-
nation with ASA decreased somewhat. ACE inhibitors and 
ARBs were frequently used in this study (at discharge 72.6% 
and 16.3%, respectively).
Subgroups with and without MetS
In the statistical comparison, there were statistically sig-
nificant differences for almost all drug classes between 
patients without MetS and those with MetS. To note major 
differences, patients with MetS had more frequent use of 
Table 2 Demographic and clinical factors in patients with and without MetS
Parameter Total 
n = 27,904
MetS 
n = 15,819
No MetS 
n = 12,085
P value*  Odds ratio* 
Demographics
Age, years 64.3 ± 11.5 64.6 ± 11.2 63.9 ± 11.8 ,0.0001
Gender, male, % 71.7 67.6 77.2 ,0.0001 0.62
Weight, kg 82.4 ± 16.1 87.0 ± 16.2 76.4 ± 13.8 ,0.0001
Body mass index, kg/m2 28.37 ± 4.78 30.0 ± 4.71 26.24 ± 3.95 ,0.0001
Waist circumference, cm 99.5 ± 13.5 105.0 ± 11.8 92.5 ± 12.2 ,0.0001
Diagnosis for CR
STEMI, % 41.1 38.7 44.3 ,0.0001 0.79 (0.76–0.83)
NSTEMI, % 21.8 21.7 21.9 0.72 0.99 (0.93–1.05)
Unstable angina pectoris, % 16.7 17.3 15.9 ,0.01 1.10 (1.04–1.18)
Therapy in acute hospital
PCI, % 55.1 52.7 58.3 ,0.0001 0.80 (0.76–0.84)
Coronary artery bypass, % 39.5 42.2 35.9 ,0.0001 1.30 (1.24–1.37)
Risk factors
Diabetes mellitus, % 35.7 52.1 14.0 ,0.0001 6.66 (6.26–7.08)
Dyslipidemia, % 97.1 97.7 96.3 ,0.0001 1.63 (1.42–1.88)
Arterial hypertension, % 86.9 94.6 76.8 ,0.0001 5.26 (4.85–5.70)
Smoking, current, % 15.7 14.4 17.5 ,0.0001 0.79 (0.74–0.85)
Smoking, previous, % 47.7 48.0 47.2 0.23 1.03 (0.98–1.08)
Peripheral arterial disease, % 12.2 12.9 11.3 ,0.0001 1.16 (1.08–1.25)
Previous stroke, % 8.8 9.4 8.0 ,0.0001 1.19 (1.10–1.30)
Positive family history, % 30.5 31.3 29.5 0.01 1.09 (1.03–1.15)
Note: *P values and odds ratios refer to the comparison between the two groups (MetS versus no MetS) at entry.
Abbreviations: MetS, metabolic syndrome; CR, cardiac rehabilitation; STEMI, ST elevation myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; PCI, 
percutaneous coronary intervention.
Table 3 Drug treatment at entry and discharge
Parameter Total 
n = 27,904
MetS 
n = 15,819
No MetS 
n = 12,085
P value* Odds ratio*
Statins, any % 79.9 → 95.2 79.7 → 95.2 80.2 → 95.4 0.30 → 0.40 0.97 → 0.95
Simvastatin, % 61.0 → 83.2 60.6 → 82.7 61.6 → 83.8 0.08 → ,0.05 0.96 → 0.92
  Dose, mg/day ± SD 30.4 ± 12.7 →  
31.3 ± 13.9
30.5 ± 12.7 →  
31.3 ± 13.9
30.3 ± 12.6 →  
31.4 ± 13.9
0.34 → 0.41
Pravastatin, % 3.8 → 2.0 3.8 → 2.0 3.8 → 2.0 0.97 → 0.85 1.00 → 1.02
Atorvastatin, % 7.0 → 4.4 7.1 → 4.5 6.7 → 4.2 0.22 → 0.37 1.06 → 1.05
Fluvastatin, % 7.9 → 5.5 8.0 → 5.7 7.8 → 5.2 0.69 → ,0.05 1.02 → 1.11
Other statin, % 0.5 → 1.8 0.5 → 1.8 0.4 → 1.8 0.24 → 0.86 1.23 → 0.98
CAI, % 7.2 → 47.2 7.6 → 47.0 6.7 → 47.3 ,0.01 → 0.65 1.14 → 0.99
ASA, % 83.8 → 84.2 83.0 → 83.4 84.8 → 85.2 ,0.0001 → ,0.0001 0.88 → 0.87
ASA + clopidogrel, % 45.2 → 42.0 42.2 → 39.0 49.2 → 46.0 ,0.0001 → ,0.0001 0.76 → 0.75
Beta blocker, % 86.2 → 89.5 87.1 → 90.3 85.0 → 88.6 ,0.0001 → ,0.0001 1.19 → 1.20
ACE inhibitor, % 71.5 → 72.6 72.0 → 73.3 70.9 → 71.6 ,0.05 → ,0.01 1.05 → 1.09
ARB, % 12.4 → 16.3 14.0 → 18.4 10.4 → 13.6 ,0.0001 → ,0.0001 1.41 → 1.44
Oral antidiabetic drug, % 15.3 → 16.9 22.9 → 25.3 5.3 → 6.1 ,0.0001 → ,0.0001 5.3 → 5.23
Insulin, % 12.3 → 12.6 18.1 → 18.5 4.7 → 4.8 ,0.0001 → ,0.0001 4.49 → 4.54
Notes: *P values and odds ratios refer to the comparison between the two groups (MetS versus no MetS) at entry. Values are percentages at entry and → at discharge.
Abbreviations: MetS, metabolic syndrome; SD, standard deviation; CAI, cholesterol absorption inhibitor; ASA, acetylic salicylic acid; ACE, angiotensin converting enzyme; 
ARB, angiotensin receptor blocker.
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Table 4 Parameters and treatment goal achievement at entry and discharge
Parameter Total 
n = 27,904
MetS 
n = 15,819
No MetS 
n = 12,085
P value* Odds ratio*
TC (mg/dL) 184.9 ± 48.0 →  
152.6 ± 36.1
184.8 ± 49.6 →  
151.0 ± 37.0
185.1 ± 45.3 →  
155.0 ± 35.2
,0.05 → ,0.0001 NA
LDL-C (mg/dL) 113.8 ± 39.1 →  
86.1 ± 28.6
113.9 ± 40.1 →  
85.4 ± 28.9
113.7 ± 37.6 →  
87.1 ± 28.0
0.26 → ,0.0001 NA
HDL-C (mg/dL) 43.2 ± 12.8 →  
43.2 ± 12.0
39.9 ± 11.1 →  
40.2 ± 10.6
48.2 ± 13.6 →  
47.7 ± 12.7
,0.0001 → ,0.0001 NA
TG (mg/dL) 157.4 ± 81.0 →  
136.1 ± 71.3
178.1 ± 94.5 →  
149.8 ± 76.1
126.0 ± 62.2 →  
115.3 ± 57.4
,0.0001 → ,0.0001 NA
Guideline achievement
LDL-C ,100 mg/dL 38.7 → 73.8 39.4 → 74.6 37.5 → 72.8 ,0.01 → ,0.01 1.08 → 1.10
TC ,200 mg/dL 66.7 → 90.3 66.4 → 90.7 67.3 → 89.8 0.12 → ,0.05 0.96 → 1.10
HDL-C . 50 (w)/ 
. 40 mg/dL (m)
44.0 → 44.4 27.4 → 30.8 69.2 → 64.9 ,0.0001 → ,0.0001 0.17 → 0.24
TG , 150 mg/dL 58.1 → 70.4 43.7 → 62.2 80.0 → 82.8 ,0.0001 → ,0.0001 0.19 → 0.34
HDL-C . 50/40 mg/dL +  
TG , 150 mg/dL
29.0 → 34.6 9.3 → 20.7 58.9 → 55.6 ,0.0001 → ,0.0001 0.07 → 0.21
LDL-C ,100 mg/dL +  
HDL-C . 50 or  
40 mg/dL + TG , 150 mg/dL
11.5 → 25.9 4.2 → 15.9 22.5 → 41.1 ,0.0001 → ,0.0001 0.15→ 0.27
Systolic/diastolic BP at entry  
and discharge (mmHg)
130.5 ± 20.3/ 
76.5 ± 11.5 →  
122.3 ± 14.4/ 
72.7 ± 9.3
132.8 ± 20.5/ 
77.2 ± 11.7 →  
123.9 ± 14.4/ 
73.1 ± 9.4
127.4 ± 19.6/ 
75.7 ± 11.2→  
120.2 ± 14.1/ 
72.2 ± 9.1
,0.0001/,0.0001 →  
,0.0001/0.0001
NA
HbA1c (%) (entry only) 6.5 ± 1.1 6.6 ± 1.1 6.1 ± 1.0 ,0.0001 NA
Creatinine (mg/dL) 1.2 ± 0.9 →  
1.3 ± 0.95
1.2 ± 0.9 →  
1.3 ± 0.95
1.2 ± 0.9 →  
1.2 ± 0.95
,0.0001 → ,0.0001 NA
Fasting blood glucose (mg/dL) 108.1 ± 33.3 →  
103.3 ± 27.0
115.08 ± 36.21 →  
108.57 ± 29.23
97.63 ± 25.01 →  
94.53 ± 20.03
,0.0001 → ,0.0001 NA
Max exercise (Watts) 77.3 ± 37.0 →  
93.7 ± 39.3
75.5 ± 36.4 →  
91.1 ± 38.8
79.3 ± 37.5 →  
96.9 ± 39.6
,0.0001 → ,0.0001 NA
Notes: *P values and odds ratios refer to the comparison between the two groups (MetS vs no MetS) at entry and (indicated by the arrow →) at discharge.
Abbreviations: MetS, metabolic syndrome; TC, total cholesterol; NA, not applicable; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein 
cholesterol; TG, triglycerides; w, women; m, men; BP, blood pressure; HbA1c, glycosylated hemoglobin (HbA1c values refer to entry visit).
ACE inhibitors and ARBs (at entry and discharge), and 
less frequent use of clopidogrel and ASA/clopidogrel 
  combinations. With respect to antidiabetic medications, 
patients with MetS had higher use of oral antidiabetic 
drugs (22.9% versus 5.3% at entry and 25.3% versus 6.1% 
at discharge) and insulin (18.1% versus 4.7% at entry and 
18.5% versus 4.8% at discharge).
Target level attainment
Total cohort
Lipid levels, other surrogate parameters, and target level 
attainment at entry and at discharge are shown in Table 4. 
In the total cohort at entry mean TC was 184.9 mg/dL, mean 
LDL-C 113.8 mg/dL, mean HDL-C 43.2 mg/dL, and mean 
TG 157.4 mg/dL.
At discharge, mean values had considerably improved 
(TC 152.6 mg/dL, LDL-C 86.1 mg/dL, and TC 136.1 mg/dL), 
while HDL-C remained unchanged.
Figure 1A–E display control rates of various lipid 
  parameters alone and in combination at entry and discharge, 
in the total cohort and by subgroup. Overall, between entry 
and discharge, control rates of lipid parameters improved 
substantially, with the exception of HDL-C. The LDL-C goal 
(,100 mg/dL) was achieved at entry by 38.7% of patients and 
at discharge by 73.8%, the TC goal (,200 mg/dL) at entry 
by 66.7% of patients and at discharge by 90.3%, the HDL-C 
goal (.50 mg/dL in women; .40 mg/dL in men) at entry by 
44.0% of patients and at discharge by 44.4%. Furthermore, 
the TG goal of ,150 mg/dL was met at entry by 58.1% of 
patients and at discharge by 70.4%. Combined lipid goals 
for HDL-C + TG were reached by 29.0% of patients at entry 
and by 34.6% at discharge; for LDL-C + HDL-C + TG by 
11.5% at entry and by 25.9% at discharge.
Mean systolic and diastolic blood pressure were decreased 
to 122/72 mmHg (entry: 130/77 mmHg), and the maximum 
exercise capacity increased to 94 Watts (entry: 77 Watts). 
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Figure 1A LDL-C control rates.
Notes: LDL-C control was defined as ,100 mg/dL.
Abbreviations: LDL-C, low density lipoprotein cholesterol; MetS, metabolic syndrome.
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Figure lB HDL-C control rates.
Notes: HDL-C control was defined as .50 mg/dL in females and .40 mg/dL in males.
Abbreviations: HDL-C, high density lipoprotein cholesterol; MetS, metabolic syndrome.
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Figure 1C TG control rates at entry and discharge.
Notes: TG control was defined as ,150 mg/dL.
Abbreviations: TG, triglycerides; MetS, metabolic syndrome.
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Mean     fasting blood glucose decreased from 108 mg/dL to 
103 mg/dL. HbA1c was only available at entry (mean: 6.5%).
Subgroups with and without MetS
Mean HDL-C was lower and mean TG were substantially 
higher in MetS patients compared to those without MetS. 
Target level attainment rates for LDL-C were somewhat 
higher for patients with MetS at entry, but much lower for 
HDL-C and TG (Table 4). This also applied for the combined 
lipid goals. This pattern did not change at the discharge 
visit, but overall control rates for all described single 
parameters (with the exception of HDL-C) had improved 
substantially.
Mean blood pressure did not differ substantially between 
groups at discharge, and was in the normal range. Exercise 
capacity was lower in patients with MetS (91 versus 97 Watts). 
Fasting blood glucose (as a component of the MetS definition), 
was higher in the MetS group and was substantially decreased 
at discharge. HbA1c was slightly worse in MetS patients 
compared to those without MetS at entry.
Discussion
The present analysis provides a snapshot of the characteristics, 
treatment, and risk factor control of patients with MetS in the 
CR setting in Germany. More than half of patients had MetS. 
Irrespective of whether MetS was present or not, patients 
experienced substantial improvement in particular with 
respect to lipid parameters, but also physical training.
Patient characteristics
Patients with or without MetS were similar in terms of gender 
distribution and age. The latter finding is notable, because in 
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Figure 1D Combined control rates (HDL-C and TG). 
Notes: HDL-C control was defined as .50 mg/dL in females and .40 mg/dL in males. TG control was defined as ,150 mg/dL.
Abbreviations: HDL-C, high density lipoprotein cholesterol; TG, triglycerides; MetS, metabolic syndrome.
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Notes: LDL-C control was defined as ,100 mg/dL. HDL-C control was defined as .50 mg/dL in females and .40 mg/dL in males. TG control was defined as ,150 mg/dL.
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patients with higher body weight myocardial events tend to 
occur at a younger age (eg, in the CRUSADE registry mean 
age at first NSTEMI was 75 years in patients with BMI 
,18.5 kg/m2, and 59 years in patients with BMI . 40 kg/m2).18 
Patients with MetS as stipulated by the definition of the 
  syndrome were more often obese, and more often had 
  diabetes mellitus and arterial hypertension. Furthermore, they 
received more antidiabetic or renin-angiotensin-aldosterone 
system acting drugs, while the utilization of lipid lowering 
drugs was similar to patients without MetS. According to our 
thorough literature search, only one small study has reported 
in detail the prevalence and profile of MetS in CR following 
acute coronary syndromes.19 In a cohort of 225 patients, age 
(66.7 years) and gender distribution (men 71%) was similar to 
our study, and a similar proportion (58%) had MetS accord-
ing to NCEP ATP III criteria, and 65% were on statins. In 
that study, 3 months’ outpatient treatment reduced the mean 
number of metabolic derangements significantly (from 3.3 
to 2.8), and owing to these changes, the prevalence of MetS 
decreased to 53% in the total cohort.
Definition of MetS
Our analysis was limited to the IDF definition of MetS, and 
we did not investigate other definitions. Milionis et al have 
stated in a comparison of three definitions (NCEP ATP III5, 
National Heart, Lung, and Blood Institute/American Heart 
Association, and IDF), that the latter markedly increased 
prevalence compared with the other criteria.20 In a Greek 
study representing the overall population, adopting the IDF 
definition increased the prevalence of MetS substantially 
compared with NCEP ATP III criteria (IDF 43.4% versus 
NCEP 24.5%).21 As this was a retrospective analysis, phy-
sicians were not aware of the MetS condition, unless they 
diagnosed it themselves. As the value of the MetS diagnosis 
(beyond its components) compared to simpler risk assessment 
tools is controversial,22,23–25 the effect on the treatment of indi-
vidual risk factors was independent from this diagnosis.
The target values for lipids,26 blood pressure,27 or blood 
glucose28 and the medication recommendations for patients 
with coronary heart disease do not differ in the CR setting29 
from patients seen by family physicians. In a previous analy-
sis of the dataset, we had noted that drug treatment in CR 
appears to have been intensified (in terms of drug classes, 
drugs, and doses) compared to previous years.17
An aspect that deserves particular attention is the physi-
cal fitness of patients. Previous studies have shown that poor 
physical fitness is associated with MetS.7,11,25 The combina-
tion of both MetS and low fitness (as evidenced by high 
heart rate $ 83 beats per minute in another study) has very 
recently been reported to be associated with an almost four-
fold increased risk for cardiovascular disease.30 In our study, 
patients in both the MetS and non-MetS groups achieved a 
considerable gain in exercise capacity (in Watts) during CR 
which might contribute to improved prognosis in the long 
term.
Treatment
Treatment rates with cholesterol absorption inhibitors 
increased substantially during CR in patients with or without 
MetS, while statins in terms of drugs and doses were 
infrequently changed. The leading statin in practice and in the 
present study was simvastatin, which is usually administered 
at doses of 20–40 mg/day for coronary heart disease 
prevention. High simvastatin doses have been associated 
with increased risk of myopathy, which might discourage 
physicians to increase doses.31 Furthermore, substantial 
combination data are available for simvastatin/cholesterol 
absorption inhibitors32 and, as in other indications (such as 
arterial hypertension or chronic heart failure), combination 
treatment appears adequate in patients who have not achieved 
their treatment targets on monotherapy.
Control of risk factors
Despite the relatively short duration of CR stays, a substantial 
improvement in lipid parameters was achieved. In particular, 
TG in the MetS group was reduced from 178 to 149 mg/dL, 
an effect that was much stronger than in the group without 
MetS. In addition, in the MetS group effects on TC, LDL-C, 
and HDL-C were stronger than in the group without MetS. 
Both groups benefited in terms of a notable blood pressure 
reduction and a reduction of fasting blood glucose at discharge 
compared to entry. If the lipid control rates as stipulated by 
the respective guidelines (eg, LDL-C target , 100 mg/dL) 
are taken into account, a substantial improvement after the 
CR stay was also noted (with the exception of HDL-C). 
Nonetheless, as in previous studies of patients with coronary 
heart disease in the primary care setting33,34 there is further 
room for improvement in the lipid values,35,36 HbA1c,37 and 
blood pressure control rates.38 Physicians in rehabilitation 
have to initiate lifestyle modifications or drug treatment 
(about 3–4 weeks), and face the complexity of coronary heart 
disease patients who often have concomitant diseases.39
Methodological aspects
Among the strengths of the registry are its prospective 
conduct, its large size and representativeness for the German 
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CR setting, as well as various quality measures (plausibility 
checks and others). However, selection bias cannot be 
excluded for physicians (those voluntarily participating in 
a registry are more likely to have an interest and probably 
increased knowledge in the topic) and patients (participants 
may be more adherent to therapy compared to those   declining). 
In addition, missing data or under-reporting of characteristics 
may decrease robustness of results. We did not collect data on 
further potentially informative parameters such as uric acid, 
pro-coagulation, or inflammatory markers.
Conclusion
We found that the proportion of patients with MetS was 
very high among patients who were enrolled in CR pro-
grams. Within a short period of, on average, 3–4 weeks, 
CR programs led to considerable improvements in patients 
irrespective of MetS status in terms of mean TC, LDL-C, and 
TG levels (HDL-C levels also improved in MetS patients). 
A substantial improvement of risk factors including hyperten-
sion and high blood glucose was achieved. Physical fitness 
that can lower the risk of cardiovascular disease improved in 
MetS patients to a stronger degree than in patients without 
MetS. While overall control rates for lipids, blood pressure, 
and blood glucose are not yet optimal, patients with MetS 
gain substantial benefit from participation in CR programs.
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